Bepirovirsen approval offers new option for treatment of chronic HBV infection
The Food and Drug Administration (FDA) has approved a new first-of-its-kind treatment option for the management of chronic hepatitis B virus (HBV) infection. Bepirovirsen is a first-in-class, HBV mRNA-directed antisense oligonucleotide. The new treatment offers patients the possibility of maintaining viral suppression once chronic treatment has ended.
The FDA approval is for the treatment of chronic HBV infection in adults without cirrhosis. Specifically, it is indicated for patients who have been on nucleoside/nucleotide analog therapy for at least 6 months, and have suppressed HBV DNA and hepatitis B surface antigen (HBsAg) levels ≤3000 IU/mL (as determined by an FDA-authorized test).
Functional cure (sustained loss of HBsAg and undetectable HBV DNA) is rare with current antiviral treatments, and some people remain on treatment indefinitely. Bepirovirsen offers a better chance of functional cure after 6 months of treatment. Trials report a functional cure rate of 19% at week 72 in those who receive bepirovirsen for 24 weeks compared to 0% in those who received placebo. Response rates were higher (26%) in patients with a lower baseline HBsAg level ≤1000 IU/mL. Common adverse effects included injection-site reactions, fever, fatigue, headache, and a temporary rise in alanine aminotransferase levels.[161]
The treatment is administered as a subcutaneous injection for 6 months, and must be used in combination with oral nucleoside/nucleotide analog therapy. For convenience, it can be self-administered after the first dose.
Bepirovirsen has not yet been incorporated into established clinical practice recommendations, and its use should only be considered in the context of its emerging evidence base, which remains limited. The European Medicines Agency (EMA) has not approved it as yet, but it is currently under review.
Globally, there were 240 million people living with chronic HBV infection in 2024, representing 2.9% of the global population.
Summary
Definition
History and exam
Key diagnostic factors
- high risk of exposure
Other diagnostic factors
- asymptomatic
- jaundice
- hepatomegaly
- ascites
- fever/chills
- malaise
- maculopapular or urticarial rash
- right upper quadrant pain
- fatigue
- nausea/vomiting
- arthralgia/arthritis
- anorexia
- dark urine or clay-colored stool
- palmar erythema
- spider angiomata
- splenomegaly
- asterixis
Risk factors
- perinatal exposure in an infant born to a hepatitis B virus (HBV)-infected mother
- high-risk sexual behaviors
- injection drug use
- born in highly endemic region
- family history of hepatitis B virus (HBV) infection, hepatocellular carcinoma (HCC), and/or chronic liver disease
- household contact with hepatitis B virus (HBV) infection
- history of incarceration
- male sex
- living with HIV
- living with hepatitis C
- blood or blood product transfusion
- healthcare workers
- hemodialysis
- solid organ transplantation
Diagnostic tests
1st tests to order
- hepatic panel
- CBC
- basic metabolic panel
- coagulation profile
- serum hepatitis B surface antigen (HBsAg)
- serum antibody to hepatitis B surface antigen (anti-HBs)
- serum antibody to hepatitis B core antigen (anti-HBc)
- serum hepatitis B e antigen (HBeAg)
- serum antibody to hepatitis B e antigen (anti-HBe)
- serum quantitative hepatitis B virus (HBV) DNA
- testing for coinfections
Tests to consider
- abdominal ultrasound
- vibration-controlled transient elastography (VCTE)
- serum liver fibrosis biomarkers
- aspartate aminotransferase-to-platelet ratio index (APRI)
- liver biopsy
- alpha-fetoprotein (AFP)
- CT/MRI abdomen
- drug resistance testing
- hepatitis B virus (HBV) genotype
Treatment algorithm
acute HBV infection
chronic HBV infection and indication for treatment: nonpregnant adult without coinfection or cirrhosis or hepatocellular carcinoma
chronic HBV infection: nonpregnant adult with cirrhosis
chronic HBV infection: nonpregnant adult with hepatocellular carcinoma
chronic HBV infection: nonpregnant adult with HIV coinfection
chronic HBV infection: nonpregnant adult with hepatitis C coinfection
chronic HBV infection: nonpregnant adult with hepatitis D coinfection
chronic HBV infection: pregnant or breastfeeding
chronic HBV infection: children
Contributors
Authors
Jawad Ahmad, MD, FRCP, FAASLD
Professor of Medicine
Division of Liver Diseases
Mount Sinai Hospital
New York, NY
Disclosures
JA declares that he has no competing interests.
Acknowledgements
Dr Jawad Ahmad would like to gratefully acknowledge Dr Sateesh R. Prakash, Dr Siddarth Verma, Dr Smruti R. Mohanty, and Dr Jared Hossack, previous contributors to this topic.
Disclosures
SRP, SV, and JH declare that they have no competing interests. SRM serves as a speaker bureau for Bristol-Myers Squibb regarding the use of entecavir for the treatment of chronic hepatitis B.
Peer reviewers
George Y. Wu, MD, PhD
Chief
Hepatology Section
Department of Medicine
University of Connecticut Health Center
Farmington, CT
Disclosures
GYW is on the medical advisory boards of Gilead Sciences and Bristol-Myers Squibb.
Lucieni Oliveira Conterno, MD, PhD
Director
Clinical Epidemiology Unit
Marilia Medical School
Sao Paulo, Brazil
Disclosures
LOC declares that she has no competing interests.
Mamun-Al-Mahtab, MB BS, MSc, MD
Chairman
Bangladesh Primary Care Research Network
Dhaka, Bangladesh
Disclosures
MAM declares that he has no competing interests.
Peer reviewer acknowledgements
BMJ Best Practice topics are updated on a rolling basis in line with developments in evidence and guidance. The peer reviewers listed here have reviewed the content at least once during the history of the topic.
Disclosures
Peer reviewer affiliations and disclosures pertain to the time of the review.
References
Key articles
Terrault NA, Lok ASF, McMahon BJ, et al. Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance. Hepatology. 2018 Apr;67(4):1560-99.Full text Abstract
European Association for the Study of the Liver. EASL clinical practice guidelines on the management of hepatitis B virus infection. J Hepatol. 2025 Aug;83(2):502-83.Full text Abstract
World Health Organization. Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection. Mar 2024 [internet publication].Full text
Ghany MG, Pan CQ, Lok AS, et al. AASLD ISDA practice guideline on treatment of chronic hepatitis B. Hepatology. 2026 Apr 1;83(4):974-97.Full text Abstract
Reference articles
A full list of sources referenced in this topic is available to users with access to all of BMJ Best Practice.
Differentials
- Hepatitis A
- Hepatitis C
- Hepatitis D
More DifferentialsGuidelines
- Clinical practice guidelines on the management of hepatitis B virus infection
- Guidelines for the prevention, diagnosis, care and treatment for people with chronic hepatitis B infection
More GuidelinesPatient information
Hepatitis B: should I have the vaccine?
More Patient informationLog in or subscribe to access all of BMJ Best Practice
Use of this content is subject to our disclaimer